MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ
1.280
-0.020
-1.54%
After Hours: 1.310 +0.03 +2.34% 19:38 04/02 EDT
OPEN
1.261
PREV CLOSE
1.300
HIGH
1.310
LOW
1.260
VOLUME
100.93K
TURNOVER
--
52 WEEK HIGH
4.190
52 WEEK LOW
0.8127
MARKET CAP
14.87M
P/E (TTM)
-0.8806
1D
5D
1M
3M
1Y
5Y
1D
Phio Pharmaceuticals Secures cGMP Manufacturing for Clinical Supply
TipRanks · 6d ago
Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manufacturer For Its Lead Compound, Ph-762, For Both Clinical Trial And Commercial Supply
Benzinga · 6d ago
PHIO PHARMACEUTICALS CORP - ENTERS AGREEMENT WITH U.S. CGMP MANUFACTURER FOR PH-762 - SEC FILING
Reuters · 6d ago
Phio signs U.S. cGMP manufacturing deal for PH-762 clinical, commercial supply
Reuters · 6d ago
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
Newsfile · 6d ago
Weekly Report: what happened at PHIO last week (0323-0327)?
Weekly Report · 6d ago
Phio Pharmaceuticals Announces Positive Clinical Data Supporting Treatment Research For Specific Carcinomas, To Be Presented March 28th
Benzinga · 03/23 11:17
Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma
Reuters · 03/23 11:04
More
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Webull offers Phio Pharmaceuticals Corp stock information, including NASDAQ: PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.